-
Dentry, T, O'Neill, J, Raj, S, Gardiner, K, Savarirayan, R.
Exploring the family experience of children aged 2-4 years receiving daily vosoritide injections: A qualitative study..
J Pediatr Nurs
77:
e167 -e176
2024
view publication
-
Tofts, L, Ireland, P, Tate, T, Raj, S, Carroll, T, Munns, CF, Knipe, S, Langdon, K, McGregor, L, McKenzie, F, et al.
Consensus Guidelines for the Use of Vosoritide in Children with Achondroplasia in Australia.
Children
11(7)
:
789
2024
view publication
-
Savarirayan, R, Hoernschemeyer, DG, Ljungberg, M, Zarate, YA, Bacino, CA, Bober, MB, Legare, JM, Högler, W, Quattrin, T, Abuzzahab, MJ, et al.
Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial..
EClinicalMedicine
65:
102258
2023
view publication
-
Savarirayan, R, De Bergua, JM, Arundel, P, Salles, JP, Leiva-Gea, A, Irving, M, Saraff, V, McDevitt, H, Salcedo, M, Nicolino, MP, et al.
THU181 Evaluation Of Bone Mineral Density In A Cohort Of Children With ACH Participating In The PROPEL 2 Study Of Infigratinib.
Journal of the Endocrine Society
7(Supplement_1)
:
bvad114.1432
2023
view publication
-
Savarirayan, R, De Bergua, JM, Arundel, P, McDevitt, H, Cormier-Daire, V, Saraff, V, Skae, M, Delgado, B, Leiva-Gea, A, Salcedo, M, et al.
THU165 PROPEL, PROPEL 2 And PROPEL OLE Studies Of Infigratinib In Children With Achondroplasia: Design And Status Of 3 Ongoing Trials.
Journal of the Endocrine Society
7(Supplement_1)
:
bvad114.1416
2023
view publication